Autoimmune Polyglandular Syndrome Type 1 (APS-1): A Rare Yet Crucial Condition to Recognize

Volume: 11 | Issue: 1 | Year 2025 | Subscription
International Journal of Immunological Nursing
Received Date:
Acceptance Date:
Published On: 2025-03-26
First Page:
Last Page:

Journal Menu

By: Lt Col Dr Regina. P.F.

*Professor, Dept. of OBG Nursing, P.K. Das College of Nursing, Ottapalam, Kerala, India.

Abstract

Autoimmune Polyglandular Syndrome Type 1 (APS-1), also known as Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED), is a rare autosomal recessive disorder caused by mutations in the AIRE (Autoimmune Regulator) gene. This syndrome is characterized by a triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency, although it can affect multiple other organ systems. APS-1 arises from a failure of central immune tolerance, resulting in autoimmunity against various endocrine and non-endocrine tissues. The clinical presentation and disease progression are highly variable, necessitating a comprehensive and individualized approach to diagnosis and management. Treatment primarily involves hormone replacement therapies, such as glucocorticoids for adrenal insufficiency, calcium and vitamin D supplements for hypoparathyroidism, and antifungal agents for candidiasis. Immunosuppressive therapies may be required for severe autoimmune complications. Despite advances in understanding the disease’s genetic and immunological basis, APS-1 remains a challenging condition due to its rarity and multisystem involvement. Early diagnosis, multidisciplinary care, and patient education are crucial for optimizing outcomes and preventing life-threatening complications. Emerging therapeutic strategies, such as targeted immunomodulation and gene therapies, hold promise for more effective disease management in the future.


Keywords : Autoimmune Polyglandular Syndrome, Type 1 AIRE gene mutations, Multisystem autoimmunity, life-threatening complications, endocrine and non-endocrine tissues.

Loading

Citation:

How to cite this article: Lt Col Dr Regina. P.F., Autoimmune Polyglandular Syndrome Type 1 (APS-1): A Rare Yet Crucial Condition to Recognize. International Journal of Immunological Nursing. 2025; 11(1): -p.

How to cite this URL: Lt Col Dr Regina. P.F., Autoimmune Polyglandular Syndrome Type 1 (APS-1): A Rare Yet Crucial Condition to Recognize. International Journal of Immunological Nursing. 2025; 11(1): -p. Available from:https://journalspub.com/publication/ijin/article=15876

Refrences:

1. Ponranjini VC, Jayachandran S, Kayal L, Bakyalakshmi K. Autoimmune polyglandular syndrome type 1. J Clin Imaging Sci. 2012;2:62. doi: 10.4103/2156-7514.103018. Epub 2012 Oct 31. PMID: 23230544; PMCID: PMC3515937.
2. Bruserud Ø, Oftedal BE, Wolff AB, Husebye ES. AIRE-mutations and autoimmune disease. Curr Opin Immunol. 2016 Dec;43:8-15. doi: 10.1016/j.coi.2016.07.003. Epub 2016 Aug 6. PMID: 27504588.
3. Ferre EM, Rose SR, Rosenzweig SD, Burbelo PD, Romito KR, Niemela JE, Rosen LB, Break TJ, Gu W, Hunsberger S, Browne SK, Hsu AP, Rampertaap S, Swamydas M, Collar AL, Kong HH, Lee CR, Chascsa D, Simcox T, Pham A, Bondici A, Natarajan M, Monsale J, Kleiner DE, Quezado M, Alevizos I, Moutsopoulos NM, Yockey L, Frein C, Soldatos A, Calvo KR, Adjemian J, Similuk MN, Lang DM, Stone KD, Uzel G, Kopp JB, Bishop RJ, Holland SM, Olivier KN, Fleisher TA, Heller T, Winer KK, Lionakis MS. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016 Aug 18;1(13):e88782. doi: 10.1172/jci.insight.88782. PMID: 27588307; PMCID: PMC5004733.
4. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. 2006 Aug;91(8):2843-50. doi: 10.1210/jc.2005-2611. Epub 2006 May 9. PMID: 16684821.
5. Sperling MA, Angelousi A, Yau M. Autoimmune Polyglandular Syndromes. [Updated 2024 Jul 21]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279152/.
6. Meager A, Visvalingam K, Peterson P, Möll K, Murumägi A, Krohn K, Eskelin P, Perheentupa J, Husebye E, Kadota Y, Willcox N. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006 Jul;3(7):e289. doi: 10.1371/journal.pmed.0030289. PMID: 16784312; PMCID: PMC1475653.
7. Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990 Jun 28;322(26):1829-36. doi: 10.1056/NEJM199006283222601. PMID: 2348835.
8. Kumar MP, Thyagarajan B, Haller N, Ciltea D. A Diagnostic Conundrum of Distributive Shock: Autoimmune Polyglandular Syndrome Type II. Indian J Crit Care Med. 2019 Dec;23(12):582-583. doi: 10.5005/jp-journals-10071-23297. PMID: 31988549; PMCID: PMC6970207.
9. Ashraf AP, Kohn B, Wilson DP. Improving Long-Term Outcomes of Youth With Lipid Abnormalities-Expanding the Role of Pediatric Endocrinologists. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4421-4426. doi: 10.1210/jc.2019-00150. PMID: 31120509.
10. Oftedal BE, Hellesen A, Erichsen MM, Bratland E, Vardi A, Perheentupa J, Kemp EH, Fiskerstrand T, Viken MK, Weetman AP, Fleishman SJ, Banka S, Newman WG, Sewell WA, Sozaeva LS, Zayats T, Haugarvoll K, Orlova EM, Haavik J, Johansson S, Knappskog PM, Løvås K, Wolff AS, Abramson J, Husebye ES. Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune Diseases. Immunity. 2015 Jun 16;42(6):1185-96. doi: 10.1016/j.immuni.2015.04.021. PMID: 26084028.

 Previous Article
Next Article